PRNewsWire
27 Oct 2025, 12:16 UTC · 47w ago
Verdict
Headline leans bearish. We score MLTX −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
MoonLake Immunotherapeutics' Phase 3 clinical trial results for its only drug candidate, sonelokimab (SLK), failed to achieve efficacy comparable to the approved competitor BIMZELX.
More negative than 99% of claims this week
MoonLake's stock price declined nearly 90%, or $55.75 per share, in a single trading session following the Phase 3 data announcement.
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 99% of claims this week
Berger Montague has filed a class action lawsuit alleging that MoonLake and its executives made false and misleading statements regarding the clinical advantages of sonelokimab.
More negative than 87% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a securities fraud class action lawsuit and reported 'disastrous' Phase 3 clinical trial results leading to a nearly 90% stock decline.
More negative than 85% of ticker scores this week
The company is the subject of a securities fraud class action lawsuit notice.
More negative than 85% of ticker scores this week
The company is the subject of a securities fraud class action lawsuit notice.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
49m ago
+33.8%
Price is moving against the score
$12.73 vs $9.52 close before publication (Oct 24) · not market-adjusted
MLTX chart →
